Jessica Hergert

Assistant Editor, OncLive®
Jessica joined the company in August 2019 and is one of the point contacts for the OncLive On Air™ podcast. She is a Rider University alumna and holds a degree in journalism and biology. Prior to joining MJH Life Sciences, she interned with the Ireland-based social media monitoring agency Olytico and served as a copy editor and writer for The Rider News. Email: jhergert@onclive.com

Articles

Brufsky Underscores Practicing-Changing Data in HER2+ Metastatic Breast Cancer

January 17th 2022

Adam M. Brufsky, MD, PhD, FACP, discusses the significance of the data from DESTINY-Breast03 with trastuzumab deruxtecan vs T-DM1 for patients with metastatic HER2-positive breast cancer, as well as how the findings set the field up to improve outcomes for patients with brain metastases.

Wealth of Newer Treatment Options Span the Scope of Multiple Myeloma and Amyloidosis

January 13th 2022

Tomer Mark, MD, discusses the emerging role of minimal residual disease as a surrogate end point in multiple myeloma, treatment selection for patients with newly diagnosed, early relapsed, and late relapsed disease, and the importance of daratumumab being introduced to the treatment paradigm of amyloidosis.

Incorporation of Chemotherapy-Free Regimens Improve Outcomes in Hematologic Malignancies

January 13th 2022

Thomas Kipps, MD, PhD, discussed navigating treatment regimens in CLL and MCL, the success of brentuximab vedotin in Hodgkin lymphoma, choosing between TKIs in CML, and the importance of transfusion independence in MDS.

ctDNA Testing Gains Ground in NSCLC With the Potential to Further Guide Treatment Decisions

January 12th 2022

Liquid biopsies are critical in understanding oncogenic drivers and resistance mechanisms in patients with non–small cell lung cancer.

NSCLC Paradigm Progresses With Adjuvant Treatment and Overcoming Resistance

January 10th 2022

As the armamentarium of advanced non–small cell lung cancer () continues to grow with the addition of novel targeted therapies for rare patient subtypes, the field is simultaneously shifting to evaluate targeted therapy and immunotherapy in earlier lines of treatment, including the neoadjuvant and adjuvant spaces.

Developments With Immunotherapy, Maintenance Therapy, and Novel Strategies Push the Field of Women’s Cancers Forward

January 6th 2022

Melissa Geller, MD, MS, and colleagues discuss key clinical trials that have changed the landscapes of HER2-positive breast cancer and triple-negative breast cancer, the role of first- and second-line maintenance therapy in ovarian cancer, and key updates in cervical and endometrial cancers.

Aggarwal Shines a Light on Precision Medicine in Lung, Breast, Ovarian, and GI Cancers

January 6th 2022

Molecular testing is an established and essential precursor to treatment for patients with non–small cell lung cancer based on the volume of actionable targets, such as EGFR and KRAS G12C mutations, as well as PD-L1 status.

Bispecific Antibodies Hold Promise in HER2+ Breast Cancer

January 5th 2022

Sara M. Tolaney, MD, MPH, discusses the mechanism of action that makes bispecific antibodies an intriguing approach in managing HER2-positive breast cancer, efficacy data with zanidatamab that were presented during the 2021 SABCS, and her thoughts on sequencing strategies with bispecific antibodies among other agents in the paradigm.

Penson Provides a Snapshot View of Switch Maintenance Therapy Selection in Recurrent Ovarian Cancer

January 4th 2022

Richard Penson, MD, MBBS, discusses how he makes treatment decisions for maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer.

Positive Phase 2 Data Set the Stage for the Pivotal ARTEST Trial With Enobosarm in ER+/AR+ Metastatic Breast Cancer

January 3rd 2022

Adam M. Brufsky, MD, PhD, FACP, discusses the rationale to evaluate enobosarm in estrogen receptor–positive, androgen receptor–positive metastatic breast cancer, prior data observed with the agent, and the unmet needs positive results of the ARTEST trial could potentially fulfill.

Questions on Quadruplets and CAR T Set to be Answered As Myeloma Paradigm Parses Out the Clinical Value of MRD

December 30th 2021

The armamentarium of multiple myeloma has expanded with the introduction of combination regimens in the up-front setting and novel targeted agents, including CAR T-cell therapy, in the relapsed/refractory setting.

Multiple Myeloma Paradigm Adapts to Novel Therapies Across Disease States

December 29th 2021

Data from key clinical trials evaluating expanded combination strategies and novel therapies have transformed the treatment paradigms of newly diagnosed, relapsed/refractory, and heavily pretreated multiple myeloma, but it remains important to contextualize the data appropriately without cross-trial comparisons.

Immunotherapy Approvals Overcome Years of Stagnation in GI Cancers

December 28th 2021

Syma Iqbal, MD, shares the main highlights from an IPC meeting, which centered on the evolving landscapes and importance of implementing best practices for patients with hepatobiliary cancers, locally advanced and advanced pancreatic cancer, advanced gastric/gastroesophageal junction cancer, and metastatic colorectal cancer.

Sequencing Strategies May Shift With Emerging Options in GI Malignancies

December 24th 2021

With the rapid uptake of novel therapies, including immunotherapy and targeted therapy, shifts in treatment strategies are anticipated in hepatobiliary cancers, locally advanced and advanced pancreatic cancer, gastric/gastroesophageal junction cancers, and metastatic colorectal cancer.

Bispecific Antibodies Like Zanidatamab Have Promise in Heavily Pretreated HER2+ Breast Cancer

December 23rd 2021

Adam M. Brufsky, MD, PhD, FACP, discusses the rationale to evaluate HER2-directed bispecific antibodies in HER2-positive breast cancer, the emergence of zanidatamab as a potential treatment strategy, and the unmet medical need the agent could fill in this disease.

FDA Approvals Signify a Successful 2021 in Lung Cancer, But Resistance to Available Therapies Remains a Top Concern

December 21st 2021

The FDA approvals of several targeted therapies, such as sotorasib, amivantamab-vmjw, and mobocertinib, as well as immunotherapeutic strategies, such as adjuvant atezolizumab, represent significant advances made in 2021 for the treatment of patients with non–small cell lung cancer.

Current Management Strategies for Desmoid Tumors Are Marked by Less Surgery, More Systemic Options

December 20th 2021

Despite their rarity, the management of desmoid tumors has been an area of significant clinical change as the field has shifted away from aggressive surgical interventions to active surveillance and systemic therapies that are less morbid for patients.

Adavosertib Elicits Efficacy in RAS/TP53+ mCRC With Potential Additive Benefit in Left-Sided Tumors

December 16th 2021

The WEE1 inhibitor adavosertib improved progression-free survival with a tolerable safety profile compared with active monitoring in patients with RAS/TP53-mutated metastatic colorectal cancer.

Neoadjuvant Trastuzumab Deruxtecan Dosed in First Patient With Early-Stage HER2+ Breast Cancer

December 16th 2021

The first patient with high-risk, early-stage HER2-positive breast cancer has received a dose of neoadjuvant fam-trastuzumab deruxtecan-nxki as part of the global, phase 3 DESTINY-Breast11 trial.

APVO436 Demonstrates Manageable Safety With Anti-Neoplastic Activity in Relapsed/Refractory AML/MDS

December 15th 2021

The investigational bispecific antibody APVO436 demonstrated tolerability with encouraging anti-neoplastic efficacy in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome, according to updated findings from an ongoing phase 1 trial.